RECELL GO® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both marketsRECELL GO is AVITA Medical’s ...
(RTTNews) - AVITA Medical, Inc. (RCEL), a regenerative medicine company focused on innovative wound care solutions, announced that the U.S. Food and Drug Administration has approved its premarket ...
VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care ...
RCEL grew its portfolio with Cohealyx and RECELL GO Mini and effectively increased its TAM by over $2 billion. Deferred purchases from Q4 2024 should help Q1 2025 figures, which positions RCEL shares ...
The FDA is asking for more information regarding Avita's Recell Go device. The Recell Go is a more automated version of an already approved product for Avita. The company said that it is now hoping to ...
VALENCIA, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class ...
VALENCIA, Calif., Sept. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) ("AVITA Medical", or the "Company"), a leading therapeutic acute wound care company, today announced ...
23d
AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data
Cohealyx® multi-center study interim analysis and new case data to be presentedRECELL® and PermeaDerm® data reinforce a comprehensive approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results